Keywords: این است; Rechute platine sensible; Chirurgie; Chimiothérapie; Allergie; Bévacizumab; Olaparib; Platinum sensitive relapse; Surgery; Chemotherapy; Drug reaction; Bevacizumab; Olaparib;
مقالات ISI این است (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: این است; 3-MA; 3-methyladenine; Asc; ascorbate; ATM; ataxia telangiectasia mutated; ATP; adenosine triphosphate; BRAF; murine sarcoma viral oncogene homolog B; Cat; catalase; Chk2; checkpoint kinase 2; CQ; chloroquine; Cys-SO3H; cysteine S-sulfate; DHA; dehydroasc
Keywords: این است; PARP inhibitors; DNA repair; Homologous recombination repair; HRD; Homologous recombination deficiency; BRCA1; BRCA2; Ovarian cancer; Olaparib;
Keywords: این است; CYP3A4; itraconazole; olaparib; pharmacokinetic; rifampin;
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
Keywords: این است; Glioblastoma; Poly(ADP-ribose) polymerase; Olaparib; Radiotherapy; O6-methylguanine methyltransferase; Dose escalation; Radiosensitizer;
Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells
Keywords: این است; HPLC-UV-DAD; Bioanalytical method validation; Intracellular drug concentration; PARP inhibitors; Olaparib;
Castalagin and vescalagin purified from leaves of Syzygium samarangense (Blume) Merrill & L.M. Perry: Dual inhibitory activity against PARP1 and DNA topoisomerase II
Keywords: این است; PARP1 inhibitor; Castalagin; Vescalagin; Olaparib; Topoisomerase; Syzygium samarangense; PARP; poly(ADP-ribose) polymerase; PAR; poly(ADP-ribose); PARylation; poly(ADP-ribosyl)ation; PARylate; poly(ADP-ribosyl)ate; ADP-ribose; ADPR; nicotinamide; Nam; CAS
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
Keywords: این است; Epithelial ovarian cancer; PARP inhibitor; Olaparib; Veliparib; Rucaparib; Niraparib;
PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice
Keywords: این است; COPD; Lung inflammation; Emphysema; NF-κB; Olaparib; PARP-1;
BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
Keywords: این است; Ovarian serous carcinoma; BRCA1; Olaparib; Comprehensive genomic profiling;
Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma
Keywords: این است; PARP inhibitor; PET; Imaging; Olaparib; Mesothelioma;
Original ArticlePoly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials
Keywords: این است; Homologous recombination repair defects; Olaparib; Growth inhibition; Patient-derived xenografts; Pharmacokinetics;
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Keywords: این است; Olaparib; Ovarian cancer; BRCA1/2 mutation; Phase II;
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer
Keywords: این است; Olaparib; Metformin; Ovarian cancer; AMPK
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
Keywords: این است; Ovarian cancer; BKM120; Olaparib; BRCA; Combination therapy;
APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
Keywords: این است; APR-246; Olaparib; p53; PARP; ROS;
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
Keywords: این است; Glioblastoma; Genotoxic stress; DNA repair; SAHA; Olaparib;
PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals
Keywords: این است; PARP-1; Type 2 DM; Diabetic cardiovascular complications; 4-aminobenzamide; Olaparib;
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
Keywords: این است; Cost-effectiveness; PARP inhibitiors; Ovarian cancer; Olaparib; BRCA
PARP inhibitors: A new era of targeted therapy
Keywords: این است; PARP inhibitors; Lynparza; Olaparib; BMN-673; Personalized medicine;
PARP Inhibitors as P-glyoprotein Substrates
Keywords: این است; olaparib; Veliparib; CEP-8983; PARP inhibitor; drug Resistance; cell lines; P-glycoprotein; cancer chemotherapy; toxicity;
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer
Keywords: این است; Pancreatic cancer; Obatoclax; Olaparib; Drug combination;
Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells
Keywords: این است; DSB repair; Non-homologous end-joining; Olaparib; Radiosensitivity; PARP1-dependent end-joining;
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
Keywords: این است; PARP; Olaparib; Rucaparib; HER2; Trastuzumab; Breast cancer;
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry assay quantifying olaparib in human plasma
Keywords: این است; Olaparib; PARP-inhibitor; LC–MS/MS; GLP; Validation; Human plasma
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Keywords: این است; Olaparib; PARP-inhibitor; Cediranib; Anti-angiogenic; Ovarian; Breast; Phase 1
Identification of miRNA modulators to PARP inhibitor response
Keywords: این است; PARP; Olaparib; miRNA; RAD51; Radiation
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Keywords: این است; BRCA1/2; Ovarian; Mutation; Methylation; Parp inhibitor; Olaparib; Veliparib
Male breast cancer: An update in diagnosis, treatment and molecular profiling
Keywords: این است; Male breast cancer; BRCA; PARP inhibitors; Olaparib; HER2; Estrogen receptor; Progesterone receptor; Trastuzumab; Trastuzumab-DM1
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Keywords: این است; DNA repair; PARP inhibitors; Olaparib; Synthetic lethality; Chemopotentiation
Triple-negative breast cancer: Novel therapies and new directions
Keywords: این است; Triple-negative; Breast cancer; PARP; Olaparib; TNBC; BSI-201; Neoadjuvant; Basal; BRCA1;